2023 World Conference on Lung Cancer (Posters)-EP07.02. Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers

Pdf Summary

This study analyzed the detection of circulating tumor DNA (ctDNA) in patients with early-stage non-small cell lung cancer (NSCLC) undergoing surgical resection. The researchers used a tumor-informed ctDNA profiling assay called RaDaR to detect ctDNA in plasma samples of patients before and after surgery. A total of 129 patients were enrolled in the study, with 88 patients having perioperative results.<br /><br />The study found that 25.2% of patients had detectable ctDNA before surgery, with higher rates of detection in patients with pathologic stage II and III NSCLC compared to stage I. However, the postoperative positivity rate was only 3.4%, lower than expected. Only three patients were positive for ctDNA after surgery, and all of them had N2 disease. Two patients are undergoing adjuvant chemotherapy, while one patient continues on adjuvant targeted therapy. One patient had persistent ctDNA positivity at 1 year without evidence of recurrence.<br /><br />Patients with detectable ctDNA before surgery had a higher recurrence rate compared to those with undetectable ctDNA. The study highlights the challenge of detecting micrometastatic disease and selecting patients for adjuvant therapy using ctDNA assessment.<br /><br />The researchers suggest that ongoing testing beyond the initial post-operative assessment may be necessary in surgically resected NSCLC patients. They are adding a 6-month collection time point for later analysis to assess its impact on recurrence-free survival. The study also found that tissue requirements for pathology limited the development of personalized assays in a significant portion of patients.<br /><br />In summary, this study provides insights into the detection of ctDNA in early-stage resected NSCLC patients. The findings support the need for continued ctDNA testing in these patients and highlight the challenges of using ctDNA assessment to select patients for adjuvant therapy. Further research is needed to better understand the clinical implications of ctDNA detection in this patient population.

Asset Subtitle

Jamie Feng

Meta Tag

Speaker Jamie Feng

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

ctDNA

NSCLC

surgical resection

plasma samples

perioperative results

recurrence

adjuvant therapy

micrometastatic disease

tissue requirements

clinical implications